MicroIslet Announces the Appointments of Dr. Christopher Marsh M.D., F.A.C.S., as Lead Transplant Advisor, and Dr. Ronald Goldblum, M.D., as Lead Clinical Development Consultant

MicroIslet Inc., (OTCBB: MIIS, http://www.microislet.com), the biotechnology company engaged in the development and commercialization of transplantation therapies for diabetes, announced that Dr. Christopher Marsh joined the Company’s Scientific Advisory Board and was named MicroIslet’s lead transplant consultant, and that Dr. Ronald Goldblum has been retained as the Company’s lead clinical development consultant. "Drs. Marsh and Goldblum bring a significant breadth of understanding and expertise to our scientific and clinical development plans," said Michael J. Andrews, MicroIslet’s chief executive officer. "The entire team at MicroIslet is looking forward to working closely with them to develop a successful transplantation therapy for diabetic patients. We are very pleased to have them join our efforts.” About Dr. Ronald Goldblum, M.D. Dr. Goldblum has over 19 years industry experience in clinical development with his most recent position as vice president in Clinical Development at Elan Pharmaceuticals, Inc. where he had a major role in the clinical development program for Tysabri. Dr. Goldblum is a rheumatologist with clinical development expertise in autoimmune disorders, immunology and inflammation, analgesia and prevention of graft rejection. He has also been vice president at Neurobiological Technologies, Inc., Algos Pharmaceuticals and Ancile Pharmaceuticals. Dr. Goldblum has filed over eight (8) INDs and has had a major role in multiple marketing application filings, both in the US and Europe. He is the author of over 32 scientific publications. About Dr. Christopher L. Marsh, M.D., F.A.C.S Dr. Marsh is the chief of the Organ Transplantation Service in the Division of General Surgery & Organ Transplantation and Co-Director of the Center for Organ and Cell Transplantation at Scripps Green Hospital. Previously, Dr. Marsh was associate professor of surgery and urology, Director of the Kidney/ Pancreas Transplantation Program and associate head of the Division of Organ Transplantation at the University of Washington Medical Center in Seattle. Dr. Marsh attended medical school and completed a urologic surgery residency at Loma Linda University in Loma Linda, California, followed by a transplantation fellowship at the Mayo Clinic in Rochester, Minnesota. Dr. Marsh is certified by the American Board of Urology and is approved by the American Society of Transplant Surgeons. He is a member of the American College of Surgeons, American Society of Transplant Surgeons, American Society of Transplant Physicians, International Pancreas and Islet Transplant Association, and American and International Liver Transplant Societies and American Urological Association. He has also served as president of the Urologic Society for Transplantation and Vascular Surgery. He currently chairs the medical advisory committee to LifeSharing, is a member of the UNOS liver an intestine committee and pancreas committee and is the chair of the regional review board for liver exceptions for Region V of UNOS. Dr. March has written more than 100 articles, chapters or abstracts and has held various positions on national and regional transplantation and organ procurement committees. Dr. Marsh’s active research activity includes clinical trials using new immunosuppressive drug regimens in liver and kidney transplants, pioneered steroid-free immunosuppression in organ transplantation and helped initiate new protocols in islet transplantation for the treatment of insulin requiring diabetes. He has expertise in liver, kidney, pancreas and pancreatic islet transplantation. About MicroIslet, Inc. MicroIslet is a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with insulin-dependent diabetes. MicroIslet has licensed several technologies from Duke University for isolation, culturing, storage and microencapsulation of insulin-producing islet cells from porcine sources. The Company believes that these technologies, and other proprietary methods developed in-house, are significant advances in the field of transplantation. MicroIslet is planning human clinical trials in the U.S., and exploring possible trials abroad. MicroIslet’s ultimate goal is to offer cell transplantation therapies for diabetic patients worldwide. The Company’s lead product, MicroIslet-PTM, consists of microencapsulated porcine islets for implantation into the abdominal cavity using a minimally invasive procedure. Microencapsulation involves surrounding islet cells with formulations of a highly biocompatible, ultra-pure biopolymer, called alginate, or other similar biocompatible polymers. The alginate coating allows insulin, glucose, oxygen and other nutrients to diffuse freely, while blocking antibodies and reducing the patient’s immune response to the implanted islet cells. It is hoped that MicroIslet-PTM will provide physiologic and self-regulating blood glucose control, thus reducing the need for insulin injections or infusions and constant blood glucose monitoring. The long-term complications associated with type 1 diabetes, such as peripheral neuropathies, heart and kidney disease, and skin disorders, may be mitigated by the tighter blood glucose control that would result from such a product. Additional information about MicroIslet can be found at http://www.microislet.com. Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "Safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including MicroIslet's working capital deficit, which includes a substantial amount of indebtedness which is matured and due on demand; MicroIslet’s need to raise substantial additional funds in order to fund its new strategy and continue as a going concern; the risks and uncertainties inherent in medical treatment discovery; development and commercialization; the risks and uncertainties associated with MicroIslet’s early stage xenotransplantation technologies; the risks and uncertainties of governmental approvals and regulation, including foreign government approvals for clinical trials outside the United States; dependence on a sole source supplier of animal parts and a sole source manufacturer of encapsulated islets for pre-clinical and clinical studies; the risks that MicroIslet’s competitors will develop or market technologies or products that are more effective or commercially attractive than MicroIslet’s products; and other risks detailed from time to time in MicroIslet’s most recent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. MicroIslet disclaims any intent or obligation to update these forward-looking statements.